PIVYA® (pivmecillinam) tablets is a penicillin class antibiotic for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible bacteria.

This website is intended for US healthcare professionals only.

Resistance Hero

Resistance

Everyday Antibiotic Stewardship in uUTI Treatment

Everyday Antibiotic Stewardship in uUTI Treatment

Familiar antibiotics are not always appropriate empiric choices. Ciprofloxacin should be reserved for patients with no alternative treatment options as a last resort.1 High resistance to trimethoprim-sulfamethoxazole (TMP-SMX) also limits empiric use: when local resistance exceeds 20% and susceptibility is unknown, another option should be considered.2

Everyday Stewardship When Treating uUTI

Antibiotic Resistance Threshold
Trimethoprim-sulfamethoxazole (TMP-SMX) Recommended as a primary first-line choice only if local resistance rates do not exceed 20%.
Fluoroquinolones (e.g., Ciprofloxacin) Reserve for patients with no alternative treatment options because of the risk of serious adverse reactions.

Rising ESBL Prevalence and Declining Susceptibility Among Uropathogens

Increasing antimicrobial resistance among urinary pathogens is limiting options for empiric treatment of uncomplicated urinary tract infections (uUTIs).

In a US surveillance study of more than 1.5 million E. coli urinary isolates collected from female outpatients between 2011 and 2019, Kaye et al. reported:3

  • 25.4% nonsusceptibility to trimethoprim-sulfamethoxazole (TMP-SMX)
  • 21.1% nonsusceptibility to fluoroquinolones
  • An increase in extended-spectrum beta-lactamase (ESBL)-positive isolates from 4.1% in 2011 to 7.3% in 2019

These findings highlight the challenges of antimicrobial resistance and the importance of considering local susceptibility patterns when selecting empiric treatment for uUTIs.

ESBL production can confer resistance to multiple beta-lactam antibiotics, further narrowing treatment options.4

In Vitro Activity Against ESBL-Positive E. coli

In a US surveillance analysis of urinary isolates collected from 2017 through 2020, 98.2% of ESBL-positive E. coli isolates were susceptible to mecillinam. Susceptibility among these isolates was 97.3% for fosfomycin, 92.4% for nitrofurantoin, 33.0% for trimethoprim-sulfamethoxazole (TMP-SMX), and 27.7% for ciprofloxacin.4

In Vitro Susceptibility of ESBL-Positive E. coli Urinary Isolates4

In Vitro Susceptibility Chart

In vitro susceptibility among ESBL-positive E. coli urinary isolates (n=224); US isolates collected 2017-2020.

Why PIVYA?

About PIVYA Icon

About PIVYA

Learn about PIVYA, a first-line treatment for uncomplicated urinary tract infections with over 40 years of clinical experience.

Learn More
Efficacy Icon

Efficacy/Safety

See the results of clinical trials in which PIVYA was evaluated against placebo, ibuprofen, and cephalexin.

View Data
Prescription Icon

Prescribing PIVYA

What to know about starting your patients on PIVYA.

Prescribing Guide

Help Your Patients Save on Their Prescription for PIVYA

Most eligible commercially insured patients pay between $0 and $15 using the PIVYA copay savings card.

PIVYA Copay Card

Request samples for your office

Click the button below to fill out an online form to receive a free sample of PIVYA.

In compliance with the Prescription Drug Marketing Act regulations, incomplete request forms cannot be processed and samples will not be delivered.

References:
  1. PIVYA (pivmecillinam) Prescribing Information. Alembic Therapeutics; 2025.
  2. US Food and Drug Administration. FDA approves new treatment for uncomplicated urinary tract infections. Published April 24, 2024. Accessed October 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections.
  3. Kaye KS, et al. Clin Infect Dis. 2025;80:280-299.
  4. Kranz J, et al. Eur Urol. 2026;90(4):413-429.
  5. Gupta K, et al. Clin Infect Dis. 2011;52(5):e103-e120.
  6. Tamma PD, et al. Clin Infect Dis. 2026; doi:10.1093/cid/ciag481.